Trading Sections
Critical Metals: Focus on the Greenland Tanbreez Project and Ambitious Analyst Target Driving the Stock
Cantor Fitzgerald initiated coverage of Critical Metals (CRML) on July 14 with a "Speculative Buy" rating...
Candel Therapeutics: Compelling Clinical Phase 3 Data and a $22 Price Target by Stifel!
Candel Therapeutics (CADL) recently published crucial Phase 3 data (PrTK03) for its lead candidate Aglatimagene...
Alpha Cognition: Zunveyl growth and new studies strengthen its profile in the Alzheimer's market
Raymond James initiated coverage of the stock of Alpha Cognition (ACOG) on July 10, 2026, with an "Outperform"...
BioAge Labs: How Novo Nordisk's ZEUS Study Could Validate the Market for the NLRP3 Inhibitor BGE-102
In mid-June 2026, BioAge Labs (BIOA) dosed the first patient in the QUELL-CV study to test the oral...
FDA Approval and Accelerated Efficacy Data: How Vera Therapeutics Addresses the Multi-Billion Dollar Kidney Disease Market with Trutakna
Classification of the FDA Decision and Market Dynamics On July 7, 2026, the California-based biotech...
AtaiBeckley: Canaccord Raises Target to $17 and Praises Progress in DMT Buccal Film Study!
The biopharma sector continues to experience steady interest in companies dedicated to developing novel...
Arcturus Therapeutics: Strategic Focus on Rare Diseases and Thermo Fisher Alliance Bring mRNA Specialists into Analyst Spotlight
Arcturus secures industry giant Thermo Fisher Scientific as a strategic partner for the phase 3 development...
Nemetschek: AI initiatives and M&A strategy underpin analyst price target of 110 euros
US bank JPMorgan maintains the Nemetschek stock rating at "Overweight" after a recent management discussion,...
Larimar Therapeutics aims to file BLA for Nomlabofusp: H.C. Wainwright expects market launch in 2027 and billion-dollar revenue
H.C. Wainwright begins coverage of the Larimar stock with a "Buy" recommendation and a price target of...
Grindr Inc.: Strategic Shift with "Edge" and "Woodwork" – Morgan Stanley Sees Peak Price Target of $29!
Grindr Inc. (GRND) operates a globally established social network for the LGBTQ+ community. The core...
Viridian Therapeutics: Advances in the TED Pipeline Support Analyst Price Targets of up to $43!
Wall Street is responding with significant price target increases to the operational developments at...
Roblox: After 67% Price Decline, Research Firm Arete Issues a Buy Recommendation - Experts See New Upside Potential Through AI Safety Features and Advertising Revenues
The research firm Arete has upgraded the Roblox stock rating from "Neutral" to "Buy" following a significant...
Eupraxia Pharmaceuticals: How Targeted Drug Release Addresses Billion-Dollar Markets – Oppenheimer Sees Massive Price Potential
From Systemic to Local Therapy: The Business Model Eupraxia Pharmaceuticals Inc. (EPRX) is a clinical-stage...
Bitdeer Technologies: Realignment to High-Performance Computing for AI Workloads Boosts Analyst Expectations – Price Target at $35
From Crypto Miner to Vertically Integrated Infrastructure Provider The Bitdeer Technologies Group...
Tenax Therapeutics Approaching Crucial Study Data: Experts See High Potential in the Cardiopulmonary Portfolio
Tenax Therapeutics (TENX) is a biopharmaceutical company in clinical phase 3, focused on the identification...
SpaceX: How Starlink V3 and Starship Successes Elevate the Company to a New Level - Arete Sees 124% Price Potential
SpaceX (SPCX) launched on June 12th under the ticker SPCX with a historic valuation of around 1.78 trillion...
Immix Biopharma: Convincing CAR-T Study Data and $2 Billion Revenue Potential Bring Focus to Stock
The Business Model and Breakthrough in Cell Therapy Immix Biopharma (IMMX) is a clinical biopharmaceutical...
Nano Nuclear Energy: With Strategic Acquisitions and AI Excitement Towards a Vertically Integrated Nuclear Future - Experts See 87% Price Potential
The renaissance of nuclear energy in global financial markets is in full swing. While traditional large...
Camp4 Therapeutics: JPMorgan Upgrade and Progress on CMP-002 Highlight RNA Pioneer
The Business Model of Targeted Gene Upregulation Camp4 Therapeutics (CAMP) is a biopharmaceutical...
Rezolute: Pipeline Progress and Buy Recommendation from Guggenheim with the Addition as "Best Idea"
The Business Model: Innovation in Rare Metabolic Diseases Rezolute (RZLT) is a clinical-stage biopharmaceutical...
Avalo Therapeutics: Phase-2 Success and Fresh Capital Fuel Biotech Hope - BofA Recommends Buy with Target of $35!
Focus on Unmet Medical Needs Avalo Therapeutics (AVTX) presents itself in the current biotech landscape...
Rigetti Computing: 108-Qubit Milestone and $100 Million Funding Drive $40 Price Target Spark Buy Interest!
Government Mandate: The US Department of Commerce signed a memorandum of understanding in May 2026...
AnaptysBio as a Pure Royalty Manager: Jemperli Dynamics and the Overlooked Imsidolimab Potential Justify $95 Price Target
AnaptysBio (ANAB) underwent a massive structural transformation in spring 2026 and now offers investors...